Categories
Change Password!
Reset Password!
Tegoprazan redefines treatment for erosive esophagitis, delivering results on par with PPIs while drawing focus to the evaluation of its long-term safety profile.
A new systematic review and meta-analysis highlights tegoprazan, a novel potassium-competitive acid blocker (P-CAB), as a promising substitute to proton pump inhibitors (PPIs) for erosive esophagitis (EE). The findings come amid growing concerns about the long-term safety of PPIs, which remain the standard therapy for acid-related disorders.
This Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)-guided study examined 3 randomized controlled trials comprising 658 patients with EE. Primary endpoints focused on endoscopic healing at 4 and 8 weeks, while secondary outcomes captured overall and drug-related treatment-emergent adverse events (TEAEs) as well as serious adverse events (SAEs), providing a precise and thorough appraisal of tegoprazan’s therapeutic impact. Tegoprazan demonstrated non-inferior healing outcomes comparable to PPIs at both 4 and 8 weeks in patients with EE (Table 1).
Overall, adverse events and SAEs showed no statistically significant difference between groups (RR = 1.19, 95% CI : 0.92–1.53; P = 0.19; I² = 24%), while drug-related TEAEs were considerably higher in the tegoprazan group (RR = 1.23, 95% CI: 1.03–1.48; P = 0.02; I2 = 0%). Investigators concluded that tegoprazan delivered healing outcomes comparable to PPIs in EE, while the higher incidence of drug-related adverse events highlighted the need for further investigation into its long-term safety before routine use.
European Journal of Gastroenterology & Hepatology
Tegoprazan vs. proton pump inhibitors for erosive esophagitis: a superior alternative or just another option? A systematic review and meta-analysis of randomized controlled trials
Muhammad Anas Nayyer et al.
Comments (0)